3 September 2025 – At its meeting, the Federal Council adopted the dispatch on the revision of the Therapeutic Products Act (Heilmittelgesetz, TPA) and submitted it to the Parliament. The TPA aims to ensure that only high-quality, safe and effective therapeutic products are placed on the market in Switzerland. With the revision, the Federal Council wants to promote digitalization in the treatment process and thus increase medication safety. Additionally, medicinal products for advanced therapies will be regulated more clearly in order to improve the population’s access to innovative forms of treatment.

Changes include the obligation to issue and redeem prescription electronically. Patients will also receive an electronic medication plan, which can be stored in the electronic patient record (Elektronisches Patientendossier, EPD). This is intended to reduce incorrect intake and increase adherence to therapy.

For more information, see here.